When asked in one of the earnings call, management did mention that their focus would be on manufacturing APIs in high volume, gradually improve the process and make these new molecules more profitable. Example, Gabapentin is facing severe competition still IOLCP went ahead to introduce this API in their portfolio.
Company is debt free and has decent amount of cash. IMO, IOLCP is not under pressure to hasten large number of successful molecules to overtake Brufin revenue
3 Likes